Studies on the anti-inflammatory properties of thalidomide: Effects on polymorphonuclear leukocytes and monocytes

Barnhill, Raymond L.; Doll, N.; Millikan, Larry E.; Hastings, Robert C.

doi:10.1016/s0190-9622(84)80458-2

Cited by 89 publications

(36 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Thus, thalidomide acts through the effect on polymorphonuclear cell functioning: it reduces phagocytosis by inhibiting polymorphonuclear leucocytes. It also inhibits monocyte phagocytosis without causing any cytotoxicity [4,21] Malondialdehyde levels were increased at the site of tissue injury. Thus, increased tissue level of malondialdehyde is used as one of the parameters to study the tissue damage via lipid peroxidation.…”

Section: Discussionmentioning

confidence: 99%

Effect of Different Doses of Thalidomide in Experimentally Induced Inflammatory Bowel Disease in Rats

Prakash

Medhi²,

Saikia

et al. 2008

Basic Clin Pharma Tox

View full text Add to dashboard Cite

The present study was carried out to evaluate the effect of different doses of thalidomide in experimentally induced inflammatory bowel disease in rats. Adult Wistar rats of either sex were used (n = 36). Colitis was induced by a single intra-colonic application of 20 mg 2,4,6-trinitrobenzene sulfonic acid (TNBS) dissolved in 35% ethanol into the descending colon. Rats were divided into six groups (n = 6). Animals were treated with vehicle (ethanol), TNBS dissolved in 35% ethanol, thalidomide (with different doses of 50, 100 and 150 mg/kg body weight), and sulfasalazine (360 mg/kg body weight) for 14 days. After completion of 14 days of treatment, animals were killed and the following parameters were assessed: morphological score, histological score and biochemical parameters (myeloperoxidase, malondialdehyde and tumour necrosis factor-α ). Results showed thalidomide with different doses provided protection against TNBS-induced colonic damage. There was significant protection with thalidomide 150 mg/kg body weight compared to controls (P < 0.001). All the biochemical parameters were highly reduced in the entire thalidomide-treated group compared to controls particularly with thalidomide 150 mg/kg body weight (P < 0.001). Treatment with thalidomide restored malondialdehyde as well as reduction of myeloperoxidase and tumour necrosis factor-α towards normal levels. Morphological and histological score were significantly reduced in all the treated groups with significant effect found with 150 mg/kg (P < 0.001). Our results indicate efficacy of thalidomide in TNBS induce experimental colitis model in rats but present findings requires further investigation to establish the real safety and efficacy in human beings.

show abstract

Section: Discussionmentioning

confidence: 99%

Effect of Different Doses of Thalidomide in Experimentally Induced Inflammatory Bowel Disease in Rats

Prakash

Medhi²,

Saikia

et al. 2008

Basic Clin Pharma Tox

View full text Add to dashboard Cite

show abstract

“…Faure et al (8) postulated that the anti-inflammatory effect of thalidomide in cutaneous diseases marked by dermal accumulation of leucocytes may be due to inhibition of leucocyte chemotaxis. This may explain the beneficial effects of thalidomide in inflammatory conditions such as pyoderma gangrenosum, recurrent mucocutaneous aphthous ulcers and Behçet's disease, which are characterized by tissue infiltration by polymorphonuclear cells (PMNs) (9). Thalidomide is used for the management of chronic recurrent/severe ENL and the effect has been attributed to its ability to inhibit inflammatory cytokines: -tumor necrosis factor alpha (TNF-a), vascular endothelial-derived growth factor (VEGF), and basic fibroblast growth factor (bFGF) in RNA processing (6).…”

Section: Discussionmentioning

confidence: 99%

Thalidomide: An experience in therapeutic outcome and adverse reactions

Sharma

Mahajan

et al. 2007

Journal of Dermatological Treatment

View full text Add to dashboard Cite

Thalidomide appears promising in a number of inflammatory dermatological conditions and will probably find new usages in future. The treating physicians need to be wary of the thrombo-embolic complications due to thalidomide especially when glucocorticoids or other chemotherapeutic agents such as doxorubicin, gemcitabine, 5-fluorouracil or dexamethasone-cyclophosphamide pulse therapy are being used concomitantly, and in patients of metastatic renal carcinoma, myelodysplastic syndrome or multiple myeloma receiving thalidomide/chemotherapy. Antiphospholipid or anticardiolipin antibodies appear to be other possible risk factors for this complication.

show abstract

“…39 It has also been shown to decrease neutrophil chemotaxis and phagocytosis 40,41 and monocyte phagocytosis. 42 Thalidomide has also been shown to inhibit angiogenesis by an unknown mechanism. 43 The study by Verheul and colleagues 44 also showed inhibition of carcinoma growth in rabbits.…”

Section: Commentmentioning

confidence: 99%

Thalidomide as a Potential Treatment for Scleromyxedema

Caradonna¹

2004

Arch Dermatol

View full text Add to dashboard Cite

with a 1-year history of skin thickening. The process began on her hands and progressed to involve her arms, face, neck, shoulders, chest, and proximal extremities. Her only systemic complaints were limited mobility of her joints, particularly her hands and wrists. Physical examination findings revealed leonine facies. The skin of the neck, shoulders, and chest exhibited 1-to 2-mm coalescent linear papules. The skin of the hands, forearms, upper arms, and trunk was sclerotic. Skin biopsy results showed marked dermal thickening, displacement of collagen bundles by mucin, and numerous spindled fibroblasts, consistent with scleromyxedema. The results of laboratory tests, including a complete blood cell count, chemistry tests, liver function tests, an antinuclear antibody panel, an extractable nuclear antigen panel, and thyroid function tests, were normal. Immunoglobulins were obtained, and the following levels were revealed: IgM, 92 mg/dL (reference range, 25-210 mg/ dL); IgA, 152 mg/dL (reference range, 40-390 mg/dL); and IgG, 1490 mg/dL (reference range, 525-1650 mg/ dL), with a light chain monoclonal gammopathy. Hematologic evaluations, including serum and urine protein electrophoresis, immunoelectrophoresis, a bone marrow examination, and radiography of the head and chest, produced no evidence of multiple myeloma.Because of significant restriction of joint mobility, the patient underwent treatment with cytotoxic agents. She was initially treated with melphalan, 16 mg/d orally (PO), plus prednisone, 100 mg/d PO, for 4 days at a time in 1-month intervals for 4 cycles from

show abstract

Studies on the anti-inflammatory properties of thalidomide: Effects on polymorphonuclear leukocytes and monocytes

Cited by 89 publications

References 25 publications

Effect of Different Doses of Thalidomide in Experimentally Induced Inflammatory Bowel Disease in Rats

Effect of Different Doses of Thalidomide in Experimentally Induced Inflammatory Bowel Disease in Rats

Thalidomide: An experience in therapeutic outcome and adverse reactions

Thalidomide as a Potential Treatment for Scleromyxedema

Contact Info

Product

Resources

About